John Eric Duda, M.D.
John Eric Duda, M.D.
Associate Professor of Neurology at the Veteran's Administration Medical Center
Department: Neurology
Contact information
Philadelphia VAMC
PADRECC/Mail Stop #127
University and Woodland Av.
Philadelphia, PA 19104
PADRECC/Mail Stop #127
University and Woodland Av.
Philadelphia, PA 19104
Office: 215-823-5934
Email:
john.duda@va.gov
john.duda@va.gov
Education:
B.S. (Psychology)
The Pennsylvania State University , 1987.
MD
Thomas Jefferson University, 1994.
Permanent linkB.S. (Psychology)
The Pennsylvania State University , 1987.
MD
Thomas Jefferson University, 1994.
Selected Publications
Weintraub, D., Dietz, N., Duda, J.E., Wolk, D., Doshi, J., Xie, S.X., Davatzikos, C., Clark, C., Siderowf, A.: Alzheimer’s disease pattern of brain atrophy predicts cognitive decline in Parkinson’s disease Brain 135(1): 170-80, January 2012.Manning, K.J., Clarke, C., Lorry, A., Weintraub, D., Wilkinson, J.R., Duda, J.E., Moberg, P.J.: Medication Management and Neuropsychological Performance in Parkinson’s Disease. The Clinical Neuropsychologist 26(1): 45-58, January 2012.
Ben Sassi, S., Nabli, F., Hentati, E., Nahdi, H., Trabelsi, M., Ben Ayed, H., Amouri, R., Duda, J.E., Farrer, M.J., Hentati, F. : Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease. Parkinsonism and Related Disorders 18: 243-6, 2012.
Ross, G.W., Duda, J.E. Abbott, R.D., Pellizzari, E., Petrovitch, H., Miller, D.B., O'Callaghan, J.P., Tanner, C.M., Noorigian, J.V., Masaki, K., Launer, L., White, L.R.: Brain Organochlorines and Lewy Pathology: The Honolulu-Asia Aging Study. Movement Disorders 27(11): 1418-24, 2012.
Milber, J.M., Noorigian, J.V., Morley, J.F., Petrovitch, H., White, L.R., Ross, W.G., Duda, J.E.: Lewy pathology is not the first sign of degeneration in vulnerable neurons in PD. Neurology 79: 2307-2314, 2012.
Morley, J.F., Xie, S.X., Hurtig, H.I., Stern, M.B., Colcher, A., Horn, S., Dahodwala, N., Duda, J.E., Weintraub, D., Chen-Plotkin, A.S., Van Deerlin, V., Falcone, D., Siderowf, A. : Genetic influences on cognitive decline in Parkinson's disease. Movement Disorders 27(4): 512-8, 2012.
Weaver, F.M., Follett, K.A., Stern, M.B., Luo, P., Harris, C.L., Hur, K., Marks, W.J., Rothlind, J., Sagher, O., Moy, C., Pahwa, R., Burchiel, K., Hogarth, P., Lai, E.C., Duda, J.E., Holloway, K., Samii, A., Horn, S., Bronstein, J.M., Stoner, G., Starr, P.A., Simpson R., Baltuch, G., De Salles, A., Huang, G.D., Reda, D.J., for the CSP 468 Study Group: Randomized trial of deep brain stimulation for Parkinson’s disease: 36 month outcomes. Neurology 79: 55-65, 2012.
Irwin, D.J., White, M.T., Toledo, J.B., Xie, S.X., Robinson, J.L., Van Deerlin, V., Lee, V.M., Leverenz, J.B., Montine, T.J., Duda, J.E., Hurtig, H.I., Trojanowski, J.Q. : Neuropathologic substrates of Parkinson disease dementia. Annals of Neurology 72: 587-98, 2012.
Hellman, A.H., Morley, J.F. and Duda, J.E.: Disease Modification in PD: Are we there yet with currently available therapies? Neurodegenerative Disease Management 2(4): 379-87, 2012.
Weintraub, D., Doshi, J., Koka, D., Davatzikos, D., Siderowf, A.D., Duda, J.E., Wolk, D.A., Moberg, P.J., Xie, S.X., Clark, C.M.: Neurodegeneration across stages of cognitive decline in Parkinson disease. Archives of Neurology 68(12): 1562-8, December 2011.